{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclosporine+ophthalmic+emulsion+Formulation+A", "query": { "intervention": "cyclosporine ophthalmic emulsion Formulation A" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cyclosporine+ophthalmic+emulsion+Formulation+A&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T22:11:31.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05322148", "title": "Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dry Eye" ], "interventions": [ { "name": "Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Research Insight LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2022-06-03", "completion_date": "2022-11-21", "has_results": false, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 3, "location_summary": "Hemet, California • Laguna Hills, California • Brecksville, Ohio", "locations": [ { "city": "Hemet", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Brecksville", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05322148" }, { "nct_id": "NCT04362670", "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dry Eye Disease" ], "interventions": [ { "name": "OTX-CSI", "type": "DRUG" }, { "name": "Placebo Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ocular Therapeutix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2020-04-23", "completion_date": "2021-08-11", "has_results": true, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 15, "location_summary": "Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04362670" }, { "nct_id": "NCT00135811", "title": "Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glomerulosclerosis, Focal" ], "interventions": [ { "name": "Cyclosporin", "type": "DRUG" }, { "name": "MMF and Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "2 Years to 40 Years" }, "enrollment_count": 207, "start_date": "2004-11", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2012-05-22", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135811" }, { "nct_id": "NCT02013791", "title": "Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dry Eye Syndromes" ], "interventions": [ { "name": "Vehicle", "type": "DRUG" }, { "name": "Sham", "type": "OTHER" }, { "name": "Cyclosporine New Ophthalmic Formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2014-04-29", "completion_date": "2017-04-12", "has_results": true, "last_update_posted_date": "2018-05-15", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 8, "location_summary": "Artesia, California • Glendale, California • Irvine, California + 5 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013791" }, { "nct_id": "NCT00833495", "title": "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allergic Conjunctivitis" ], "interventions": [ { "name": "Prednisolone Acetate 0.12% (Pred Mild®)", "type": "DRUG" }, { "name": "FOV1101-00", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% (Pred Forte®)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fovea Pharmaceuticals SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2009-01", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-03-09", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833495" }, { "nct_id": "NCT07224529", "title": "Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Meibomian Gland Dysfunction (MGD)" ], "interventions": [ { "name": "Vevye(Cyclosporine 0.1% Ophthalmic Solution)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2026-06-01", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224529" }, { "nct_id": "NCT03656926", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-03-26", "completion_date": "2024-03-12", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656926" }, { "nct_id": "NCT00795132", "title": "Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukaemia", "Chronic Disease", "Leukemia", "Myelodysplasia", "Lymphoma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2004-04", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795132" }, { "nct_id": "NCT03657342", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2019-03-26", "completion_date": "2024-04-16", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657342" }, { "nct_id": "NCT01319773", "title": "Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dry Eye Syndromes" ], "interventions": [ { "name": "cyclosporine ophthalmic emulsion Formulation A", "type": "DRUG" }, { "name": "cyclosporine ophthalmic emulsion Formulation B", "type": "DRUG" }, { "name": "cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%", "type": "DRUG" }, { "name": "cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%", "type": "DRUG" }, { "name": "cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2010-11", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-09-01T22:11:31.214Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319773" } ] }